lymphoma

(redirected from CTCL.)
Also found in: Dictionary, Thesaurus, Medical.

lymphoma,

a cancer of the tissue of the lymphatic systemlymphatic system
, network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. The lymphatic system functions along with the circulatory system in absorbing nutrients from the small intestines.
..... Click the link for more information.
. There are two categories of lymphomas. One type is termed Hodgkin's diseaseHodgkin's disease,
a type of cancer of the lymphatic system. First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. Incidence peaks in young adults and the elderly.
..... Click the link for more information.
, the other, non-Hodgkin's lymphoma (see lymphoma, non-Hodgkin'slymphoma, non-Hodgkin's,
any cancer of the lymphoid tissue (see lymphatic system) in which the Reed-Sternberg cells characteristic of Hodgkin's disease (the other category of lymphoma) are not present.
..... Click the link for more information.
). See also neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.
.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/

lymphoma

[lim′fō·mə]
(medicine)
Any neoplasm, usually malignant, of the lymphoid tissues.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Features Helpful in Differential Diagnosis of Nodal Involvement by [CD30.sup.+] CTCL and CHL Cutaneous [CD30.sup.+] Classical Hodgkin T-Cell Lymphoma Lymphoma Clinical History of skin B-symptoms, mediastinal involvement by CTCL. or multifocal nodal Involved lymph nodes in involvement at drainage region of skin presentation.
Table 1: Demographic profile and basic data of 95 patients with primary CTCL. Age (years) Range 7-84 Median 40.5 Mean ([+ or -] SD) 41.7 [+ or -] 16.9 Sex Male 42 (44.2%) Female 53 (55.8%) Latent period (years) Range 0-55 Median 1 Mean ([+ or -] SD) 4.43 [+ or -] 8.38 TNM stage IA 38 (40%) IB 43 (45.7%) IIA 2 (2.1%) IIB 3 (3.2%) III 4 (4.2%) IV 5 (5.3%) Table 2: Characteristics of PCTCL by WHO-EORTC classification in Isfahan, Iran.
Despite an overall positive experience with the use of ECP in CTCL, differences in study design, including the ECP proto cols used; participants' baseline characteristics; clinical definition of response; length of treatment and staging of CTCL prior to study entry, make it difficult to properly evaluate the use of ECP in CTCL. Results from subsequent studies also show that the role of ECP in treating some stages of CTCL may be limited.
The full approval of ONTAK, which is an orphan drug indicated for a rare disease, is in keeping with our human health care mission, to address the unmet medical needs of patients with CTCL. Eisai remains committed to make further contributions to patients with CTCL.
The size of immunoglobulin H macules, however, is tiny compared with what you'll see with CTCL. The absence of scales makes eczema, psoriasis, or tinea corporis very unlikely.
It was the largest global randomised clinical trial of systemic therapy in CTCL.
TABLE 1: Demographic profile and basic data of 95 patients with primary CTCL. Age (years) Range 7-84 Median 40.5 Mean ([+ or -]SD) 41.7 [+ or -] 16.9 Sex Male 42 (44.2%) Female 53 (55.8%) Latent period (years) Range 0-55 Median 1 Mean ([+ or -]SD) 4.43 [+ or -] 8.38 TNM stage IA 38 (40%) IB 43 (45.7%) IIA 2 (2.1%) IIB 3 (3.2%) III 4 (4.2%) IV 5 (5.3%) TABLE 2: Characteristics of PCTCL by WHO-EORTC classification in Isfahan, Iran.
Currently, there is an ongoing phase 3 (NCT00419367) clinical study for patients with advanced CTCL. (69) Based on the studies thus far, while vorinostat has not definitively demonstrated an improved outcome in patients with CTCL, the therapy provides a relatively safe alternative to the currently existing systemic treatments.
Duvic also presented information on bexarotene at the annual meeting of the American Academy of Dermatology in San Francisco, where she released final numbers from phase II-III randomized trials for patients with early- and advanced-stage CTCL.
The indication includes patients diagnosed with all stages of refractory CTCL. At the request of the FDA, Ligand has agreed to conduct certain post approval Phase IV clinical and pharmacokinetic studies.
Spectrum Pharmaceuticals announced results from a prospective Phase 2 single-arm, open-label, multicenter clinical trial studying the management of oral mucositis with the use of oral leucovorin as adjunct to FOLOTYN in patients with hematological malignancies, including PTCL and CTCL. Study results with a total of 35 patients demonstrated that use of leucovorin 25 mg tablets by oral administration for two days, initiated 24 hours after each FOLOTYN dose reduced the rate of Grade 2 or greater mucositis significantly, to 5.7 percent from historic rate associated with FOLOTYN use.